I am very happy to share the special theme issues of Applied Health Economics and Health Policy for “Genomic Technologies’ Health Economics” jointly edited with DeIRRE WEYMANN and ILIAS GORANITIS.
This special issue includes 12 papers that summarize existing evidence of the value attached to the use of genome technology in various clinical situations and present new health evidence for the United States, Australia, Canada, Scotland and Thailand.
We also wrote an editor to reflect the discovery of this paper and emphasizes the challenges and opportunities of the horizon for health economists.
The conclusions are as follows:
Twelve papers on this theme issue provide a comprehensive overview of the current evidence and research focus in the field of health economy and genome, which has evolved considerably over the past 20 years. Today, more and more health economists apply cutting -edge methods to cherish the cost and benefits of innovative genome mediation as a potential to change population health and welfare.
But there is a challenge on the horizon. Many publications in this theme problem have a clear policy relevance, but in this clinical situation, economic evidence is unclear that it actually provides information to medical decisions. Especially for non -traditional health technology evaluation evidence and evidence obtained from the actual data. Some jurisdiction areas have increased the possibility of patient preference information, and actual evidence of health technology regulations and repayment is increasing, but anxiety still remains. In order to absorb this health and economic evidence into a precision medical decision, it is formal and harmonious and requires stake -centered guidelines.
The second task is the speed of new applications of genome technology. This special issue takes a widespread consideration of the value of genome information in certain cancer, rare diseases or chronic diseases. These cases are likely to be a sub -set of all applications in the future. There is a growing interest in understanding the costs and advantages of newborn genome sequencing, multi -wicked risk scores and multiple cancer early detection tests. In health economics, there is a more generally shift to stock beneficial economic evaluation, and genome is one of the contexts that basically affect the value estimation of stocks and fairness. Finally, there is an increasing need to understand the value of genome in certain geographical contexts, such as the value of genome, low -income and intermediate income national environments at the population (macro) level. To date, health economists have never studied these topics of genome science. This should be changed in the next few years, and we are happy to know how this field is continuing to develop in the next decade.
Welcome all thoughts!
